Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study.

Pan Xiang, Chengyuan Yang, Ruoyi Shen, Xiaoxiong Huang, Xuerong Huang, Qi Cheng, Zongping Luo, Qin Zhang

Abstract read

In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Integrating genetic, epigenetic, and clinical signatures via machine learning for robust prediction of leflunomide response in rheumatoid arthritis: a multi-center validation study.Frontiers in immunology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pan XiangDepartment of Orthopaedics, First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215000, Jiangsu, China.

Chengyuan YangDepartment of Orthopaedics, First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215000, Jiangsu, China.

Ruoyi ShenDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.

Xiaoxiong HuangDepartment of Orthopaedics, Ningbo No. 2 Hospital, Ningbo, 315010, Zhejiang, China.

Xuerong HuangDepartment of Neonatology, Women and Children, s Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, China.

Qi ChengDepartment of Orthopaedics, First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215000, Jiangsu, China.

Zongping LuoDepartment of Orthopaedics, First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215000, Jiangsu, China.

Qin ZhangDepartment of Orthopaedics, First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215000, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the increasing availability of therapeutic drugs for autoimmune diseases, many patients still struggle to achieve their treatment goals. Our aim was to identify whether drugs originally used to treat bone density could be applied to the treatment of autoimmune diseases through Mendelian randomization (MR). Methods: Using summary statistics from genome-wide association studies, we used a two-sample MR design to estimate the correlation between autoimmune diseases and BMD-related drug targets. Data from the DrugBank and ChEMBL databases were used to identify the drug targets of anti-osteoporosis medications. The Wald ratio test or inverse-variance weighting method was used to assess the impact of genetic variation in drug target(s) on autoimmune disease therapy. Results: Through our analysis, we discovered a negative correlation between genetic variability in a specific gene ( Conclusion: These results indicate a possible link between genetic differences in the drug targeting

Indexed as

Autoimmune diseasesBone mineral densityDrug re-purposingESR1Mendelian randomization

Identifiers

PMID39130432

DOI10.1016/j.heliyon.2024.e34494

PMCPMC11315135

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.